GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2006

Celgene Procures API Manufacturing Plant for $46.5M

  • Celgene acquired an API manufacturing facility from Siegfried in a deal worth $46.5 million. Celgene will make an initial payment of $12.5 million for the assets. The manufacturing facility will initially will be used to produce Revlimid.

    This API manufacturing plant has been approved by U.S. and European regulatory authorities to produce and supply drug substances for both of these markets. Siegfried will continue to collaborate with Celgene to provide chemical intermediates, quality control systems, analytical testing, and other technical support services.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »